ASX
LCT 0.077    Last updated 5.39 pm
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Cell therapy for neurodegenerative diseases

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

 

Our lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

 

A Phase IIb trial of NTCELL for Parkinson's disease is currently underway. It aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. If the trial is successful LCT will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease, in 2017.

 

In addition to Parkinson’s disease, NTCELL has the potential to be used in a number of other central nervous system indications, including Huntington’s, Alzheimer’s and motor neurone diseases including amyotrophic lateral sclerosis (ALS).

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges and is incorporated in Australia, with operations based in New Zealand.

— 23 June 2016

NTCELL® trial results to be presented in Berlin

As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safety and clinical effects of NTCELL in patients with Parkinson’s disease at the 20th International Congress of Parkinson’s Disease and Movement Disorders in Berlin. The presentation, in the form of a poster entitled “Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up” takes place at 12 noon Berlin time today.

Read More Read Less

— 8 June 2016

Appendix B

New issue announcement, application for quotation of additional securities and agreement

Read More Read Less
Load More

— 1 March 2016

LCT expects crucial Parkinson’s clinical trial results in early 2017

Australasian biotech company Living Cell Technologies says it will know the outcome of a make-or-break clinical trial on its regenerative cell therapy for Parkinson's disease in the first quarter of next year. If the trial succeeds, Living Cell's lead product NTCELL will be the world's first disease-modifying treatment for Parkinson's as existing treatments only deal with the symptoms rather than stopping the degeneration of the brain.

Read More Read Less
Load More
— 23 June 2016

20th International Congress of Parkinson’s Disease and Movement Disorders. Principal Investigator Barry Snow, MD is presenting a poster at the Congress Scientific Program Committee of the 20th International Congress of Parkinson’s Disease and Movement Disorders, in Berlin, Germany. The details of the poster presentation are as follows: Abstract number: 1952 Abstract title: Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up Poster session topic: Parkinson's disease: Clinical trials, pharmacology and treatment Presentation Date: 23 June 2016 Presentation time: 12:00 – 13:30 Location: Exhibit Hall located in Hall B, Level 2 City Cube Berlin Messe Berlin GmbH Messedamm 22 14055 Berlin Germany

Load More
Announcements

— 23 June 2016

NTCELL® trial results to be presented in Berlin

As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safety and clinical effects of NTCELL in patients with Parkinson’s disease at the 20th International Congress of Parkinson’s Disease and Movement Disorders in Berlin. The presentation, in the form of a poster entitled “Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up” takes place at 12 noon Berlin time today.

Read More Read Less

— 8 June 2016

Appendix B

New issue announcement, application for quotation of additional securities and agreement

Read More Read Less
Load More
LCT in the News

— 1 March 2016

LCT expects crucial Parkinson’s clinical trial results in early 2017

Australasian biotech company Living Cell Technologies says it will know the outcome of a make-or-break clinical trial on its regenerative cell therapy for Parkinson's disease in the first quarter of next year. If the trial succeeds, Living Cell's lead product NTCELL will be the world's first disease-modifying treatment for Parkinson's as existing treatments only deal with the symptoms rather than stopping the degeneration of the brain.

Read More Read Less
Load More
Events
— 23 June 2016

20th International Congress of Parkinson’s Disease and Movement Disorders. Principal Investigator Barry Snow, MD is presenting a poster at the Congress Scientific Program Committee of the 20th International Congress of Parkinson’s Disease and Movement Disorders, in Berlin, Germany. The details of the poster presentation are as follows: Abstract number: 1952 Abstract title: Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up Poster session topic: Parkinson's disease: Clinical trials, pharmacology and treatment Presentation Date: 23 June 2016 Presentation time: 12:00 – 13:30 Location: Exhibit Hall located in Hall B, Level 2 City Cube Berlin Messe Berlin GmbH Messedamm 22 14055 Berlin Germany

Load More